hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06301516 id: HM20027823 id: R41MH133540 type: NIH link: https://reporter.nih.gov/quickSearch/R41MH133540 briefTitle: Impact VR: An Emotion Recognition and Regulation Training Program for Youth With CD overallStatus: RECRUITING date: 2024-02-16 date: 2024-12 date: 2024-12 date: 2024-03-08 date: 2024-03-08 name: Virginia Commonwealth University class: OTHER name: National Institute of Mental Health (NIMH) briefSummary: Conduct disorder (CD) is one of the most prevalent childhood psychiatric disorders. Unfortunately, there are limited treatments available for CD. The present study aims to test an innovative virtual reality intervention called Impact VR for symptom reduction in a sample of 60 youth with CD. conditions: Conduct Disorder conditions: Conduct Disorders in Children conditions: Conduct Disorders in Adolescence conditions: Callous-Unemotional Traits studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Randomized clinical trial of psychological intervention. Once all assessments are completed, the treatment group allocation will be disclosed to the administrating researcher, youth, and caregiver. This blinded approach to block randomization prevents any bias from occurring during the assessment phase by the researcher. primaryPurpose: PREVENTION masking: NONE count: 60 type: ESTIMATED name: Virtual Reality name: Comparative Control measure: Assess the preliminary efficacy of Impact Virtual Reality (VR) in reducing Callous-Unemotional traits measure: Assess the preliminary efficacy of Impact Virtual Reality (VR) in reducing Conduct disorder measure: Assess the preliminary efficacy of Impact Virtual Reality (VR) in reducing Conduct Problems measure: Assess the preliminary efficacy of Impact Virtual Reality (VR) in reducing Emotion regulation measure: Assess the preliminary efficacy of Impact Virtual Reality (VR) in reducing Emotion recognition sex: ALL minimumAge: 10 Years maximumAge: 17 Years stdAges: CHILD facility: Virginia Commonwealth University status: RECRUITING city: Richmond state: Virginia zip: 23298 country: United States name: Nicholas Johnson role: CONTACT phone: 804-828-6386 email: Nicholas.Thomson@VCUHealth.org lat: 37.55376 lon: -77.46026 hasResults: False
nctId: NCT06301503 id: 0103/UN14.2.2.VII.14/LT/2024 briefTitle: Postoperative Quality of Recovery After Combined Lumbar Plexus-Sciatic Nerve Block (LPB-SNB) overallStatus: RECRUITING date: 2024-03-08 date: 2024-04-20 date: 2024-04-25 date: 2024-03-08 date: 2024-04-11 name: Udayana University class: OTHER briefSummary: The goal of this clinical trial is to evaluate the efficacy of lumbar plexus-sciatic nerve block (LPB-SNB) by comparing the postoperative quality of recovery as assessed by the Quality of Recovery-40 (QoR-40) questionnaire, in patients who received a combination of LPB-SNB versus patients who received the traditional intravenous opioid, after lower extremity orthopaedic surgeries with spinal anaesthesia.
Researchers will then compare the results between both groups to see if the combined lumbar plexus-sciatic nerve block successfully provides adequate analgesia and enhance postoperative quality of recovery after lower extremity orthopaedic surgeries. conditions: Lower Extremity Surgery studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: One hundred participants are to be randomly assigned by a computer-generated random number table into two parallel groups and 1:1 allocation to either receive a combination of LPB-SNB or no block at all. primaryPurpose: TREATMENT masking: SINGLE maskingDescription: Numbers were prepared in sealed envelopes prepared by a third party not involved in the study to ensure allocation concealment, and handed over to the anesthetist performing the block before surgery. Participants would be blinded to the group allocation. whoMasked: PARTICIPANT count: 100 type: ESTIMATED name: USG Guided Combined LPB-SNB with Isobaric Bupivacaine name: Control measure: Postoperative Quality of Recovery as assessed by the QoR-40 questionnaire measure: Postoperative Intravenous Opioid Consumption measure: Postoperative Analgesia Duration sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Prof. Dr. I.G.N.G. Ngoerah General Hospital status: RECRUITING city: Denpasar state: Bali zip: 80114 country: Indonesia name: Tjokorda GA Senapathi, Professor role: CONTACT phone: +6281337711220 email: tjoksenapathi@unud.ac.id name: Tjokorda GA Senapathi, Professor role: SUB_INVESTIGATOR name: Pontisomaya Parami, Consultant role: SUB_INVESTIGATOR name: Made Wiryana, Professor role: SUB_INVESTIGATOR name: I Made G Widnyana, Doctorate role: SUB_INVESTIGATOR name: I Putu P Suarjaya, Doctorate role: SUB_INVESTIGATOR name: I Gusti NM Aribawa, Doctorate role: SUB_INVESTIGATOR name: Ida Bagus KJ Sutawan, Consultant role: SUB_INVESTIGATOR name: Georgina M Tiberias, MD role: SUB_INVESTIGATOR lat: -8.65 lon: 115.21667 hasResults: False
nctId: NCT06301490 id: Taif university briefTitle: The Effect of Myofascial Release in Patients With Subacromial Impingement Syndrome overallStatus: COMPLETED date: 2024-01-11 date: 2024-02-15 date: 2024-03-02 date: 2024-03-08 date: 2024-04-24 name: Taif University class: OTHER briefSummary: BACKGROUND: Shoulder pain has been reported to be the third most common musculoskeletal presentation in primary care, after low back pain and knee pain. The prognosis for those presenting with musculoskeletal shoulder pain varies greatly amongst individuals, with 50% of people reporting symptoms 6 months after presenting in primary healthcare. Functional limitations, in addition to pain, are widespread and can interfere with job, hobbies, social, and sporting activities. They may also relate to psychological discomfort and a lower quality of life. Continuous computer uses without a break, awkward postures, and the duration and frequency of laptop use have all been identified as risk factors for musculoskeletal diseases. The most prevalent cause, accounting for 70% of cases, is rotator cuff dysfunction. Rotator cuff disorders are frequently associated with short and long-term impairment and discomfort, with approximately fifty percent of patients experiencing pain or functional restrictions for up to two years. The majority of shoulder pain concerns are treated in primary care by physiotherapists and general practitioners. Myofascial release is a common hands-on method manual therapy technique that uses carefully guided low load, long duration mechanical pressures to modify the myofascial complex with promising results in improving functional level.
METHOD: The design of this study is a double blinded Randomize control trail. Forty-two participants will be divided into one of two groups, group one will have strengthening exercises, range of motion exercise, and ice application, group two will perform the same exercises with ice application plus myofascial release. Patient will be followed for one month, two session per week and the session duration will be 30-45 mins. Assessment and re-assessment will be done by independent physical therapist. All patients will be assessed by using quick DASH, VAS, ROM, and Kessler psychological distress scale. conditions: Subacromial Impingement Syndrome studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 36 type: ACTUAL name: Myofascial Release measure: pain intensity measure: disability measure: rang of motion measure: psychological distress, and health-related quality of life (HRQoL) sex: ALL minimumAge: 20 Years maximumAge: 60 Years stdAges: ADULT facility: Taif University city: Taif state: Makkah zip: 11099 country: Saudi Arabia lat: 21.27028 lon: 40.41583 hasResults: False
nctId: NCT06301477 id: 23/109X briefTitle: PRecisiOn Microbiome Directed ExtensiOn of Anti-TNFα Crohn's Disease ThErapy in Children: The PROMOTE Trial acronym: PROMOTE overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2027-03-01 date: 2027-03-01 date: 2024-03-08 date: 2024-03-12 name: Children's Hospital of Eastern Ontario class: OTHER briefSummary: To determine whether a specific food-origin plant-derived resistant starch (RS) optimized for the individual will increase the abundance of known butyrate producing microbes. conditions: Inflammatory Bowel Diseases conditions: Crohn Disease studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: A single-center, randomized, placebo-controlled, double-blinded, pilot trial primaryPurpose: BASIC_SCIENCE masking: QUADRUPLE maskingDescription: The treating physician, study participants, and research coordinators and lab researchers will not have knowledge of the randomization codes and will be blinded as to study product allocation. Unblinding will occur only if necessary to ensure study participants safety. Only Dr. Mack (Co-PI) will request to break the blind for safety reasons. Once the blind is broken by Dr. Mack the patient will be discontinued from study product. whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 45 type: ESTIMATED name: Resistant Starch name: Placebo measure: Measure of butyrate production by assessing expression of enzymes using metaproteomic/transcriptomic analysis measure: Measure of butyrate production by assessing production of shorty-chain-fatty-acids including butyrates using metabolomics analysis measure: Measure of butyrate production by assessing increases in butyrate producers using metagenomics/16S analysis measure: Change in intensification as measured by anti-TNFa dose escalation measure: Change in intensification as measured by anti-TNFa interval shortening measure: Change in disease activity measure: Changes in intestinal mucosal inflammation by measuring fecal calprotectin through stool samples measure: Changes in biomarkers of inflammation by measuring c-reactive protein through blood samples measure: Changes in patient reported disability outcomes as measured by the IBD Disability Index Questionnaire measure: Changes in patient reported quality of life outcomes as measured by the IMPACT III Questionnaire measure: Changes in parent/caregiver reported quality of life outcomes as measured by the IMPACT III-P sex: ALL minimumAge: 8 Years maximumAge: 16 Years stdAges: CHILD facility: Children's Hospital of Eastern Ontario city: Ottawa state: Ontario zip: K1H 8L1 country: Canada name: David Mack, MD, FRCPC role: CONTACT phone: (613)737-7600 phoneExt: 2516 email: dmack@cheo.on.ca name: Ruth Singleton, RN, CCRP role: CONTACT phone: (613)737-7600 phoneExt: 4123 email: rsingleton@cheo.on.ca name: David Mack, MD, FRCPC role: PRINCIPAL_INVESTIGATOR name: Alain Stintzi, PhD role: PRINCIPAL_INVESTIGATOR lat: 45.41117 lon: -75.69812 hasResults: False
nctId: NCT06301464 id: B-2003-603-103 briefTitle: Pepsinogen II and Helicobacter Pylori Test in Gastric Cancer overallStatus: ACTIVE_NOT_RECRUITING date: 2003-03-01 date: 2024-12-31 date: 2025-12-31 date: 2024-03-08 date: 2024-03-08 name: Seoul National University Bundang Hospital class: OTHER briefSummary: The aim of this study to validate the role of pepsinogens in gastric cancer screening. conditions: Gastric Cancer studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: CROSS_SECTIONAL count: 24000 type: ESTIMATED measure: The level of serum pepsinogens sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Seoul National University Bundang Hospital city: Seongnam-si state: Gyeonggi-do zip: 463-707 country: Korea, Republic of lat: 37.43861 lon: 127.13778 hasResults: False
nctId: NCT06301451 id: XD2021-1 briefTitle: Efficacy and Safety of Portable Hydrogen Rich Water Machine is Used for Adjuvant Treatment of Patients With Hyperlipidemia overallStatus: RECRUITING date: 2022-04-01 date: 2024-12-01 date: 2024-12-01 date: 2024-03-08 date: 2024-03-08 name: Sun Jia class: OTHER briefSummary: In the past 30 years, the blood lipid level of the Chinese population has gradually increased, and the prevalence of dyslipidemia patients has increased significantly. Hyperlipidemia is a disease caused by abnormal blood lipid levels, also known as abnormal lipid metabolism. Common clinical indicators include total cholesterol (TC), triglyceride (TG), low-density lipoprotein (LDL) and high-density lipoprotein ( HDL).The number of patients with abnormal blood lipid levels in China accounts for as high as 40% of the total. It is estimated that between 2010 and 2030,cardiovascular disease events will increase by 9.2 million, which seriously endangers human health and becomes a high risk factor for various cardiovascular diseases, such as atherosclerosis. One of the pathological foundations of atherosclerosis is that abnormal lipid levels in the body cause a large amount of lipid to be deposited in the arterial endothelial matrix, which is phagocytosed by smooth muscle and macrophages to form foam cells.
Hydrogen, the lightest and smallest molecular gas in the atmosphere, is considered a novel antioxidant that reduces oxidative stress. Accumulating evidence from various biomedical fields in clinical studies and experimental models of many diseases suggests that hydrogen inhalation or drinking hydrogen-containing solutions can be used as a therapeutic strategy. Due to the special physical properties of hydrogen gas that is easy to diffuse, hydrogen molecules can penetrate cell membranes to reach organelles and cell nuclei. Hydrogen's moderate reducing properties make it effective in reducing cytotoxicity, protecting nuclear DNA and mitochondria, and reducing the risk of lifestyle-related diseases and cancer.
nctId: NCT06301438 id: LY2024-022-A briefTitle: Dalpiciclib in HR+/HER2- ABC overallStatus: NOT_YET_RECRUITING date: 2024-04-25 date: 2025-12 date: 2028-12 date: 2024-03-08 date: 2024-04-16 name: RenJi Hospital class: OTHER briefSummary: To evaluate the efficacy and safety of dalpiciclib in patients with HR-positive/HER2-positive advanced breast cancer. conditions: Advanced Breast Cancer studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 103 type: ESTIMATED name: dalpiciclib measure: Progression-Free Survival measure: Adverse events sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Renji Hospital, School of Medicine, Shanghai Jiaotong University city: Shanghai zip: 200127 country: China lat: 31.22222 lon: 121.45806 hasResults: False
nctId: NCT06301425 id: TROPHY-AML01 briefTitle: MRD Response-adapted Allo-HSCT for Adverse-risk AML overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2027-05-01 date: 2028-05-01 date: 2024-03-08 date: 2024-03-08 name: Peking University People's Hospital class: OTHER name: Ruijin Hospital name: Wuhan TongJi Hospital name: Anhui Provincial Hospital briefSummary: This TROPHY-AML01 regimen aims to identify the effectiveness and safety of MRD response-adapted allo-HSCT for adverse-risk acute myeloid leukemia in an open-label, randomized, controlled trial. conditions: Acute Myeloid Leukemia studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 178 type: ESTIMATED name: Intervention group name: Control group measure: Event-free survival (EFS) measure: Relapse measure: Leukemia-free survival (LFS) measure: Non-relapse mortality (NRM) measure: Overall survival (OS) measure: Acute graft-versus-host disease (aGvHD) measure: Chronic graft-versus-host disease (cGvHD) sex: ALL minimumAge: 16 Years maximumAge: 65 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06301412 id: COTTIS-2_Version4.0-13Nov23 briefTitle: Combination of Hypothermia and Thrombectomy in Acute Stroke acronym: COTTIS-2 overallStatus: NOT_YET_RECRUITING date: 2024-03-18 date: 2026-03-18 date: 2026-06-18 date: 2024-03-08 date: 2024-03-08 name: University of Freiburg class: OTHER name: European Union name: E+E CRO consulting, Vienna, Austria name: Center for Medical data science, University of Vienna, Austria briefSummary: The goal of this clinical trial is to test the combination of hypothermia and endovascular treatment in acute stroke patients with large vessel occlusion.
Researchers will compare the intervention group (hypothermia and endovascular treatment and best medical treatment including iv thrombolysis) and control group (only endovascular treatment and best medical treatment including iv thrombolysis) to see if additional hypothermia leads to a better outcome after 3 months without relevant complications. conditions: Ischemic Stroke conditions: Large Vessel Occlusion conditions: Endovascular Treatment studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 400 type: ESTIMATED name: hypothermia measure: functional outcome measure: infarction volume measure: increase in infarction measure: recanalization result measure: neurological improvement measure: outcome at discharge measure: shift in functional outcome measure: very good clinical outcome measure: mortality measure: Length of ventilation measure: Length of stay measure: body temperature measure: time to groin puncture measure: time to recanalization measure: Occurrence of intracerebral haemorrhage (ICH) measure: Complications associated with hypothermia sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06301399 id: Rituximab01 briefTitle: Rituximab Combined With Prior Therapy in Advanced Hepatocellular Carcinoma: Efficacy & Safety Study overallStatus: NOT_YET_RECRUITING date: 2024-03-20 date: 2025-12-31 date: 2026-12-31 date: 2024-03-08 date: 2024-03-08 name: Tianjin Medical University Cancer Institute and Hospital class: OTHER briefSummary: Evaluation of the efficacy and safety of adding rituximab after failure of target immunotherapy in the Posterior treatment of advanced hepatocellular carcinoma conditions: Advanced Hepatocellular Carcinoma studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 20 type: ESTIMATED name: Rituximab+PD-1 or PD-L1 inhibitors+targeted therapy measure: ORR measure: PFS measure: OS measure: DoR measure: DCR sex: ALL minimumAge: 17 Years maximumAge: 79 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Tianjin Medical University Cancer Institute & Hospital city: Tianjin state: Tianjin zip: 300060 country: China lat: 39.14222 lon: 117.17667 hasResults: False
nctId: NCT06301386 id: EVOLUTION briefTitle: Everolimus Combined With PD-1 in Advanced Colorectal Cancer Patients overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2026-05-01 date: 2026-12-01 date: 2024-03-08 date: 2024-03-08 name: Fudan University class: OTHER name: Anyang Tumor Hospital briefSummary: The goal of this clinical trial is to learn about efficacy of Everolimus in combination with PD-1 in patients with locally advanced and advanced colorectal cancer that cannot be R0 resected. The main question is to explore the survival time, safety and tolerability of the treatment. At the same time, the correlation between biomarkers (including PD-L1 expression, tumor mutation load, lymphocyte subpopulation, cytokines, TCR, intestinal microbes, and others) and the efficacy and drug resistance mechanism will be analyzed, so as to provide reference for the subsequent guidance of the screening of benefit groups. conditions: Colon Cancer studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 25 type: ESTIMATED name: Everolimus name: PD-1 measure: objective response rate (ORR) measure: progression-free survival (PFS） measure: overall survival (OS) measure: disease control rate (DCRs) measure: advert events sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Anyang Tumor Hospital city: Anyang state: Henan country: China name: Yanjun Wang, PhD role: CONTACT phone: +8613837266702 email: m13837266702@163.com lat: 36.096 lon: 114.38278 facility: Fudan University Shanghai Cancer Center city: Shanghai state: Shanghai country: China name: Dawei Li, PhD role: CONTACT phone: +8613774201693 email: li_dawei@fudan.edu.cn lat: 31.22222 lon: 121.45806 hasResults: False
nctId: NCT06301373 id: SYSKY-2023-1185-02 briefTitle: Methotrexate Combined With Tofacitinib in Rheumatoid Arthritis overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2030-04-01 date: 2030-04-01 date: 2024-03-08 date: 2024-03-08 name: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University class: OTHER briefSummary: Rheumatoid arthritis (RA) is the leading cause of disability in Chinese women. We established a synovial pathology queue in the early stage and proposed a new synovial immunopathology classification. We found that baseline myeloid stromal RA patients had severe conditions and poor outcome. Early identification of synovial myeloid stromal RA patients and intensified treatment are key to improving RA efficacy.
This project aims to conduct a randomized, controlled, open label, multicenter clinical study on early intensified treatment of RA based on synovial pathology classification. 130 adult patients with synovial myeloid stromal type of primary treatment moderate to severe active RA were planned to be enrolled in three centers: Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University; Shenshan Medical Center, Memorial Hospital of Sun Yat-Sen University, and Guangzhou Panyu Central Hospital. They were randomly divided into an intensive treatment group and a conventional treatment group in a 1:1 ratio. The intensive treatment group was treated with methotrexate combined with tofacitinib, while the conventional treatment group was treated with methotrexate monotherapy. The expected intervention period is 12 weeks, with a follow-up period of 48 weeks. The primary endpoint is the proportion of subjects who achieved ACR20 at week 12. Secondary endpoint indicators include improvement in disease activity and joint function among subjects at different follow-up points, safety, and the proportion of subjects who experienced joint destruction progression at week 48.